Compare Biogen Inc (BIIB) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Biogen Inc trades at $191.25 (market cap $28.34B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.72. The key difference: Biogen Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | GPTY | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.63 | $50.52 |
52-Week Low | $122.68 | $34.73 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
GPTY trades at $43.50, down 2.2% today, with technical indicators showing mixed signals amid neutral overall momentum. The ETF maintains consistent weekly dividend distributions, with recent payouts ranging from $0.30-$0.38. Support levels cluster around $43-44 while resistance sits at $45-46. Recent coverage highlights GPTY's focus on AI and tech exposure through option premium strategies, though some analysts question sustainability of current performance levels.
The outlook remains balanced with income generation from weekly dividends offset by technical weakness. Key risks include concentration in tech sector volatility and dependency on option strategy performance. Analyst sentiment appears divided between income-focused appeal and concerns about NAV erosion potential in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
